BioAegis Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of Gelsolin, an Immune Regulator, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)
22. Oktober 2024 00:30 ET
|
BioAegis Therapeutics
Global 600 patient study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. Rhu-pGSN is an immune system regulator that interrupts the...
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
12. September 2024 16:56 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
LIXTE Biotechnology Holdings announces collaboration on a New Colon Cancer Clinical Trial
14. Juni 2024 11:00 ET
|
Lixte Biotechnology Holdings, Inc.
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE...
GRI Bio Announces Reverse Stock Split
14. Juni 2024 08:05 ET
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
06. Juni 2024 08:30 ET
|
Lixte Biotechnology Holdings, Inc.
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology...
Global Neutropenia Market Competitive Analysis and Forecast Report to 2028, Featuring BeyondSpring Pharmaceuticals, Coherus Biosciences, Myelo Therapeutics and Spectrum Pharmaceuticals
15. März 2024 05:14 ET
|
Research and Markets
Dublin, March 15, 2024 (GLOBE NEWSWIRE) -- The "Global Neutropenia Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis" report has been added to ResearchAndMarkets.com's...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27. Februar 2024 15:52 ET
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
Food Allergy Market to Witness Remarkable Growth, Key Insights, and Global Outlook Revealed in New 2031 Forecast Report
06. Februar 2024 10:06 ET
|
Research and Markets
Dublin, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The "Food Allergy Market: Industry Size, Share, Competition, Trends, Growth Opportunities and Forecasts by Region - Insights and Outlook by Product, 2024 to...
Psoriasis Global Market Report 2024: Market to Surge to $39.17 Billion by 2028, Middle East Poised for Rapid Growth - Long-term Forecasts to 2033
26. Januar 2024 03:17 ET
|
Research and Markets
Dublin, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The psoriasis market is undergoing significant...
US Food Allergen Testing Market Outlook to 2028 - New York Commands Attention in the Eastern Region with Innovative Allergens Detection Technology
14. Dezember 2023 11:08 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "US Food Allergen Testing Market Outlook to 2028" report has been added to ResearchAndMarkets.com's offering. With the increasing prevalence of food...